Alice Marie Stek

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi Effect of pregnancy on emtricitabine pharmacokinetics
    A M Stek
    Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA
    HIV Med 13:226-35. 2012
  2. ncbi Immunomodulatory factors in cervicovaginal secretions from pregnant and non-pregnant women: a cross-sectional study
    Jan Walter
    Department of Plant Pathology and Microbiology, University of California, Riverside, USA
    BMC Infect Dis 11:263. 2011
  3. ncbi Reduced lopinavir exposure during pregnancy
    Alice M Stek
    Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA
    AIDS 20:1931-9. 2006
  4. ncbi Antiretroviral medications during pregnancy for therapy or prophylaxis
    Alice Marie Stek
    University of Southern California School of Medicine, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 1640 Marengo Street, 300, Los Angeles, CA 90033, USA
    Curr HIV/AIDS Rep 6:68-76. 2009
  5. ncbi Lopinavir tablet pharmacokinetics with an increased dose during pregnancy
    Brookie M Best
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, USA
    J Acquir Immune Defic Syndr 54:381-8. 2010
  6. ncbi Antiretroviral therapy during pregnancy and the risk of an adverse outcome
    Ruth E Tuomala
    Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Boston 02115, USA
    N Engl J Med 346:1863-70. 2002
  7. ncbi Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women
    Edward P Acosta
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 48:430-6. 2004
  8. ncbi Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022
    Jane Hitti
    University of Washington, Seattle, 98195, USA
    J Acquir Immune Defic Syndr 36:772-6. 2004

Detail Information

Publications8

  1. ncbi Effect of pregnancy on emtricitabine pharmacokinetics
    A M Stek
    Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA
    HIV Med 13:226-35. 2012
    ..The aim of the study was to describe emtricitabine pharmacokinetics during pregnancy and postpartum...
  2. ncbi Immunomodulatory factors in cervicovaginal secretions from pregnant and non-pregnant women: a cross-sectional study
    Jan Walter
    Department of Plant Pathology and Microbiology, University of California, Riverside, USA
    BMC Infect Dis 11:263. 2011
    ....
  3. ncbi Reduced lopinavir exposure during pregnancy
    Alice M Stek
    Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA
    AIDS 20:1931-9. 2006
    ..Pregnancy can alter antiretroviral pharmacokinetics. Our objective was to describe lopinavir/ritonavir (LPV/r) pharmacokinetics during pregnancy...
  4. ncbi Antiretroviral medications during pregnancy for therapy or prophylaxis
    Alice Marie Stek
    University of Southern California School of Medicine, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, 1640 Marengo Street, 300, Los Angeles, CA 90033, USA
    Curr HIV/AIDS Rep 6:68-76. 2009
    ..However, potential adverse effects are of concern, and questions remain as to the optimal treatment strategy. More data on the effects of antiretrovirals during pregnancy are needed...
  5. ncbi Lopinavir tablet pharmacokinetics with an increased dose during pregnancy
    Brookie M Best
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, USA
    J Acquir Immune Defic Syndr 54:381-8. 2010
    ..This study determined lopinavir exposure with an increased dose of the new tablet formulation during the third trimester...
  6. ncbi Antiretroviral therapy during pregnancy and the risk of an adverse outcome
    Ruth E Tuomala
    Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Boston 02115, USA
    N Engl J Med 346:1863-70. 2002
    ..Some studies suggest that combination antiretroviral therapy in pregnant women with human immunodeficiency virus type 1 (HIV-1) infection increases the risk of premature birth and other adverse outcomes of pregnancy...
  7. ncbi Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women
    Edward P Acosta
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 48:430-6. 2004
    ..These PK results suggest that SQV-RTV at 800/100 mg b.i.d. appears to be a reasonable treatment option for this population...
  8. ncbi Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022
    Jane Hitti
    University of Washington, Seattle, 98195, USA
    J Acquir Immune Defic Syndr 36:772-6. 2004
    ..To compare the safety of nelfinavir and nevirapine-based antiretroviral treatment in HIV-1-infected pregnant women...